Boston Scientific (BSX) Stock

Assess the anticipated performance of Boston Scientific (BSX) for the quarter that ended in December 2024. Instead of just focusing on the usual revenue and profit predictions from Wall Street, let's take a closer look at some important metrics for a deeper understanding.

As the expenses for AI models decrease, as shown by the more affordable DeepSeek model from China, MedTech companies creating AI-driven solutions such as SYK, BSX, and TEM are expected to benefit.

Boston Scientific is anticipated to show significant growth in the Asia Pacific region during the fourth quarter, driven by strong performance in China and Japan.

At the end of the last trading day, Boston Scientific (BSX) was priced at $102.27, which represents a 0.32% increase compared to the previous day.

We have just put together a list of the 12 Best Fundamental Stocks to Buy Right Now. In this article, we will examine how Boston Scientific Corporation (NYSE:BSX) compares to the other top fundamental stocks available. On Friday, January 24, the S&P 500 index dropped by 0.3% to close at 6,101.24, changing its previous trend.

Boston Scientific (BSX) finished the last trading day at $101.64, which is an increase of 1.33% compared to the day before.

Boston Scientific (BSX) finished the last trading day at $98.66, which is an increase of 0.5% compared to the day before.

The first phase of the ADVANTAGE AF clinical trial has shown that the FARAPULSE™ Pulsed Field Ablation System is safe and effective for treating drug-resistant, symptomatic, persistent atrial fibrillation. Additionally, a sub-analysis from the OPTION clinical trial indicates that the WATCHMAN FLX™ Left Atrial Appendage Closure Device has consistent safety and efficacy results after cardiac ablation, whether used together or separately. Boston Scientific Corporation shared this data during a late-breaking science session at the AF Symposium 2025.

Boston Scientific's latest purchases have brought in many products that have great potential.